These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27903712)

  • 1. The myeloma stem cell concept, revisited: from phenomenology to operational terms.
    Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K
    Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
    Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
    Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification and targeting of multiple myeloma stem cells].
    Hosen N
    Nihon Rinsho; 2015 May; 73(5):816-22. PubMed ID: 25985637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
    Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
    Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
    Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
    Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cells in multiple myeloma.
    Ghosh N; Matsui W
    Cancer Lett; 2009 May; 277(1):1-7. PubMed ID: 18809245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.
    Gocke CB; McMillan R; Wang Q; Begum A; Penchev VR; Ali SA; Borrello I; Huff CA; Matsui W
    Mol Cancer Ther; 2016 Nov; 15(11):2733-2739. PubMed ID: 27573425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
    Pilarski LM; Mant MJ; Belch AR
    Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concise review: Defining and targeting myeloma stem cell-like cells.
    Abe M; Harada T; Matsumoto T
    Stem Cells; 2014 May; 32(5):1067-73. PubMed ID: 24449391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
    Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
    Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.
    Blatt K; Herrmann H; Stefanzl G; Sperr WR; Valent P
    Oncotarget; 2016 Oct; 7(40):65627-65642. PubMed ID: 27582537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
    Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
    Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cancer stem cells in multiple myeloma.
    Gunes EG; Gunes M; Yu J; Janakiram M
    Trends Cancer; 2024 Aug; 10(8):733-748. PubMed ID: 38971642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multiple myeloma stem cell].
    Hosen N
    Nihon Rinsho; 2015 Jan; 73(1):47-51. PubMed ID: 25626303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.
    Paíno T; Ocio EM; Paiva B; San-Segundo L; Garayoa M; Gutiérrez NC; Sarasquete ME; Pandiella A; Orfao A; San Miguel JF
    Haematologica; 2012 Jul; 97(7):1110-4. PubMed ID: 22315496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the biology and treatment of multiple myeloma.
    Varterasian ML
    Curr Opin Oncol; 1999 Jan; 11(1):3-8. PubMed ID: 9914870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma Propagating Cells, Drug Resistance and Relapse.
    Karadimitris A; Chaidos A; Caputo V; Goudevenou K; Ponnusamy K; Xiao X
    Stem Cells; 2015 Nov; 33(11):3205-11. PubMed ID: 26302895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.
    Hajek R; Okubote SA; Svachova H
    Br J Haematol; 2013 Dec; 163(5):551-64. PubMed ID: 24111932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.